Rebreathing-induced Hypoxia and Glucose Levels

Sponsor
University of Texas at Austin (Other)
Overall Status
Recruiting
CT.gov ID
NCT05422430
Collaborator
(none)
30
1
2
34.4
0.9

Study Details

Study Description

Brief Summary

The aim of this research project is to determine the effect of repeated maximal voluntary apneas on glucose uptake during an oral glucose tolerance test in healthy individuals, individuals with prediabetes and patients with type 2 diabetes.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Rebreathing-induced hypoxia
  • Behavioral: Spontaneous breathing
N/A

Detailed Description

It is predicted that 1 in 3 adults will develop diabetes by 2050, implying that a large percentage of the population will become at high risk for cardiovascular disease, the most common cause of death in patients with type 2 diabetes. While regular exercise reduces insulin resistance and the elevated glucose levels associated with type 2 diabetes, only 28% of the adult population with diabetes meet physical activity recommendations. There is therefore an urgent need to identify alternative, non-pharmacological interventions that prevent and treat type 2 diabetes.

A reduced oxygen availability, or hypoxia, is widely implicated in the development of insulin resistance. Paradoxically, hypoxia also triggers glucose uptake independently from the actions of insulin. Indeed, breathing low levels of oxygen stimulates glucose uptake in skeletal muscles by activating 5' adenosine monophosphate-activated protein kinase (AMPK). Discrepancies on the effect of hypoxia on glucose homeostasis may be attributed to the duration and type (nocturnal vs. diurnal) of hypoxic exposure. For example, the many severe hypoxic bouts associated with obstructive sleep apnea are associated with a worsened glycemic control while hypoxic exposure consisting of a limited number of short bouts of moderate hypoxia improves glycemic control. Therefore, an intervention that can induce brief hypoxic conditions, as observed through a reduced fraction of inspired oxygen, could attenuate the postprandial increase in glucose levels.

Fraction of inspired oxygen can be reduced by rebreathing into a low-volume closed-circuit system containing ambient air for few minutes. Thus, the aim of this research project is to determine the effect of few bouts of rebreathing-induced hypoxia on glucose uptake during an oral glucose tolerance test in healthy individuals, individuals with prediabetes and patients with type 2 diabetes. If our expected outcomes are met, our next step will be to determine whether repeated sessions of rebreathing-induced hypoxia (5 sessions per week over 1-3 months) results in improvements in glycemic control.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Effect of Rebreathing-induced Hypoxia on the Response to an Oral Glucose Tolerance Test
Actual Study Start Date :
Oct 21, 2021
Anticipated Primary Completion Date :
Sep 1, 2022
Anticipated Study Completion Date :
Sep 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Sham Comparator: Spontaneous breathing

Participants will be spontaneously breathing during an oral glucose tolerance test.

Behavioral: Spontaneous breathing
Participants will be spontaneously breathing during an oral glucose tolerance test.

Experimental: Rebreathing-induced hypoxia

Participants will rebreathe room air from a low-volume closed-circuit system for a period of 2 minutes.

Behavioral: Rebreathing-induced hypoxia
Participants will rebreathe room air from a low-volume closed-circuit system for a period of 2 minutes.

Outcome Measures

Primary Outcome Measures

  1. Change in plasma glucose levels [Collected at min 0, 30, 60, 90 and 120 minutes of the oral glucose tolerance test]

    Plasma glucose levels obtained from a venous catheter during a 2-hour oral glucose tolerance test

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Men and women aged 18 to 80 years old
Exclusion Criteria:
  • Have uncontrolled stage 2 hypertension (˃140/90 mmHg)

  • Are smokers

  • Are pregnant

  • Have a history of cardiovascular disease or indication of cardiovascular disease such as myocardial infarction, left ventricular hypertrophy, ischemic heart disease (or prior ischemia), stroke, and/or other vascular disease

  • Have a history of lung disease

  • Are taking insulin or more than one antihypertensive medication

  • Have poorly controlled diabetes: HbA1c levels ˃ 9%

  • Have been previously diagnosed with diabetic complications (nephropathy, neuropathy, retinopathy) by their family doctor

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Unviersity of Texas at Austin Austin Texas United States 78712

Sponsors and Collaborators

  • University of Texas at Austin

Investigators

  • Principal Investigator: Sophie Lalande, UT Austin

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Sophie Lalande, Assistant Professor, University of Texas at Austin
ClinicalTrials.gov Identifier:
NCT05422430
Other Study ID Numbers:
  • STUDY00001555
First Posted:
Jun 16, 2022
Last Update Posted:
Jun 16, 2022
Last Verified:
Jun 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 16, 2022